Trenk D, Wagner F, Jähnchen E, Plänitz V
Division of Clinical Pharmacology, Rehabilitationszentrum, Bad Krozingen, Federal Republic of Germany.
J Clin Pharmacol. 1987 Dec;27(12):988-93. doi: 10.1002/j.1552-4604.1987.tb05602.x.
The pharmacokinetics of the centrally acting alpha-2 agonist moxonidine were investigated in 12 healthy male subjects after single and repeated oral doses (q12h for five days) of moxonidine 0.2 mg. Plasma concentration-time data followed the general characteristics of a one-compartment model with first-order absorption. Peak plasma concentrations of 1.29 +/- 0.32 ng/mL were achieved 0.74 +/- 0.35 hours after ingestion of a 0.2-mg tablet. The terminal half-life of elimination was 2.12 +/- 0.58 hours. The oral clearance (CL/F) amounted to 830 +/- 171 mL/min with renal elimination being the major route of elimination. No significant differences in pharmacokinetic parameters could be observed following repeated dosing over five days.
在12名健康男性受试者中,研究了中枢作用性α-2激动剂莫索尼定单次及重复口服给药(0.2毫克,每12小时一次,共五天)后的药代动力学。血浆浓度-时间数据符合具有一级吸收的单室模型的一般特征。服用0.2毫克片剂后0.74±0.35小时达到的血浆峰浓度为1.29±0.32纳克/毫升。消除的终末半衰期为2.12±0.58小时。口服清除率(CL/F)为830±171毫升/分钟,肾脏排泄是主要的消除途径。连续五天重复给药后,药代动力学参数未观察到显著差异。